Abdulla Azizov, the Director of the Development Agency for the Pharmaceutical Sector, recently undertook a series of visits to enterprises in the Surkhandarya region to gain insights into their operations and offer practical assistance. These visits aim to foster growth and development within the pharmaceutical sector in Uzbekistan.
The first stop on Azizov's itinerary was the Uzbek-Indian joint venture, Nova Pharm. The company is currently a key player in the pharmaceutical industry, producing a variety of medicines, including tablets, syrups, and capsules. Notably, Nova Pharm has achieved a milestone by introducing its 25th type of tablet medicine.
Looking ahead, the company has ambitious plans to launch a project in 2024, with the goal of producing a remarkable $1mn types of soft drugs by 2025. Additionally, a new project, valued at $2mn, is set to be initiated as part of the company's expansion strategy.
Moving forward, Azizov visited Alpomish Servis Invest, a prominent Uzbek company operating in the Muzrabad district. Alpomish Servis Invest is capitalizing on the entrepreneurial opportunities provided within the country, leading to the expansion of its activities.
The month of December is expected to witness the commencement of operations at "Osiyo Darmon servis," a manufacturing enterprise with a promising future. This venture, valued at $2mn, is poised to produce one-time infusion systems utilizing cutting-edge technologies imported from China. The establishment of this enterprise is projected to create around 100 job opportunities, contributing to both economic growth and employment in the region.
Follow Daryo's official Instagram and Twitter pages to keep current on world news
Comments (0)